Clinical Trials Arena on MSN3d
Merck KGaA’s lupus drug fails in SLE cohort of Phase II trialMerck’s lupus drug enpatoran has failed to meet the primary endpoint in a subgroup of patients, but the drug's development is ...
GlobalData on MSN6d
Merck KGaA reports YE24 earnings growth amid SpringWorks acquisition talksWhile the company is in discussions to acquire SpringWorks, it did not elaborate on these talks in its earnings call.
One of Merck KGaA’s leading immunology assets has flunked a phase 2 lupus trial. | One of Merck KGaA’s leading immunology ...
Merck KGaA expects earnings and sales growth this year after reporting a rise in annual earnings on temporarily reduced ...
Merck KGaA on Thursday forecast currency-adjusted operating earnings growth of up to 8%, helped by demand for semiconductor ...
Asian News International on MSN2d
Merck Foundation CEO Together with First Ladies of Africa Mark International Women's Day 2025 Through Their 'More Than a Mother' CampaignIndia], March 11: Merck Foundation, the philanthropic arm of Merck KGaA Germany, together with First Ladies of Africa and ...
In a report released today, Matthew Weston from UBS maintained a Buy rating on Merck KGaA (0O14 – Research Report), with a price target of ...
The list price of Mavenclad is around £2,050 per 10mg tablet, although, Merck is providing it to the NHS in England at a ...
Full Year 2024 Results Key Financial Results Revenue: €21.2b (flat on FY 2023). Net ...
Q4 2024 Results Conference Call March 6, 2025 8:00 AM ETCompany ParticipantsFlorian Schraeder - Head of Investor ...
In a report released today, James Quigley from Goldman Sachs maintained a Buy rating on Merck KGaA (0O14 – Research Report), with a price ...
Germany’s Merck KGaA expects earnings and sales growth this year after reporting a rise in annual earnings on temporarily reduced research and development expenses in its healthcare segment and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback